APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

Citations Over TimeTop 1% of 2015 papers

Abstract

We have sequenced 463 presenting cases of myeloma entered into the UK Myeloma XI study using whole exome sequencing. Here we identify mutations induced as a consequence of misdirected AID in the partner oncogenes of IGH translocations, which are activating and associated with impaired clinical outcome. An APOBEC mutational signature is seen in 3.8% of cases and is linked to the translocation-mediated deregulation of MAF and MAFB, a known poor prognostic factor. Patients with this signature have an increased mutational load and a poor prognosis. Loss of MAF or MAFB expression results in decreased APOBEC3B and APOBEC4 expression, indicating a transcriptional control mechanism. Kataegis, a further mutational pattern associated with APOBEC deregulation, is seen at the sites of the MYC translocation. The APOBEC mutational signature seen in myeloma is, therefore, associated with poor prognosis primary and secondary translocations and the molecular mechanisms involved in generating them.

Related Papers

• → Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution(2018)163 cited
• → Molecular origins of APOBEC-associated mutations in cancer(2020)80 cited
• → APOBEC driving genomic evolution in ER+/HER2- breast cancer(2020)1 cited
• → Data from APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses(2023)
• → 2313P APOBEC mutagenesis and macrophage infiltration in cancer(2023)